Application of hospital-community linkage management model among residents with polyps detected by colonoscopy in colorectal cancer high-risk groups in Nanchang City, China

Start Date16 Sep 2024

Sponsor / Collaborator

Jiangxi Provincial Cancer Hospital

NCT06140589 / RecruitingNot ApplicableIIT

Study on the Efficacy, Safety and Cost-effectiveness of Cadonilimab in the Treatment of Cervical Cancer

Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.

Start Date07 Sep 2024

Sponsor / Collaborator

Fujian Cancer Hospital

[+2]

NCT06496308 / RecruitingPhase 3IIT

A Multicenter, Open-label, Randomized Controlled Study of Orelabrutinib in Combination With Bendamustine and Rituximab Versus Bendamustine and Rituximab in the Treatment of Transplant-Ineligible, Intermediate- to High-Risk Mantle Cell Lymphoma (MCL)

This multicenter, open-label, randomized controlled trial aims to evaluate the efficacy and safety of Orelabrutinib in combination with Bendamustine and Rituximab (OBR) versus Bendamustine and Rituximab (BR) in patients with intermediate- to high-risk mantle cell lymphoma (MCL) who are ineligible for transplantation. The primary objective is to assess the complete response (CR) rate during the induction phase, with secondary objectives including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Exploratory analysis will investigate the correlation between tumor biomarkers and treatment efficacy.

Start Date10 Jul 2024

Sponsor / Collaborator

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

[+7]

100 Clinical Results associated with Jiangxi Provincial Cancer Hospital

0 Patents (Medical) associated with Jiangxi Provincial Cancer Hospital

418

Literatures (Medical) associated with Jiangxi Provincial Cancer Hospital

31 Dec 2024·BioengineeredQ4 · BIOLOGY

RETRACTED ARTICLE: MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4

Q4 · BIOLOGY

ArticleOA

Author: Huang, Xianbao ; Li, Wuping ; Li, Ziye ; Li, Fei ; Lu, Wei ; Qi, Ling

Xianbao Huang, Ling Qi, Wei Lu, Ziye Li, Wuping Li and Fei Li. MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4. Bioengineered. 2021 Oct. doi: 10.1080/21655979.2021.1997697.Since publication, significant concerns have been raised about the compliance with ethical policies for human research and the integrity of the data reported in the article.When approached for an explanation, the authors provided some original data but were not able to provide all the necessary supporting information. As verifying the validity of published work is core to the scholarly record's integrity, we are retracting the article. All authors listed in this publication have been informed.We have been informed in our decision-making by our editorial policies and the COPE guidelines.The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted.'

27 Oct 2024·2024 IEEE International Conference on Image Processing (ICIP)

Dcctnet: Kidney Tumors Segmentation Based On Dual-Level Combination Of Cnn And Transformer

Author: Qin, Yipeng ; Hou, Bingzhen ; Zhang, Guimei ; Liu, Huiqun ; Chen, Ying

01 Oct 2024·The Lancet Respiratory Medicine

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

Article

Author: Cheng, Ying ; Luo, Feng ; Han, Baohui ; Shi, Jianhua ; Guo, Qi-Sen ; Jie, Zhijun ; Nagrial, Adnan ; Wang, Huaqing ; Huang, Lan ; Feng, Jifeng ; Guo, Qi-sen ; Kloecker, Goetz ; Ye, Feng ; Bazhenova, Lyudmila ; Zhao, Jun ; Oliff, Ira A ; Yao, Yu ; Li, Helen ; Oliff, Ira ; Hu, Chunhong ; Kiberu, Andrew ; Mowat, Rex B ; Liu, Chunling ; Zhang, Yiping ; Du, Lihua ; Cheng, Gongyan ; Pan, Hongming ; Jennens, Ross ; Wang, Zhongkun ; Jain, Vikram ; Liu, Zhihua ; Wu, Huijuan ; Lu, Junguo ; Hrom, John S ; Karim, Nagla A ; Wu, Yanping ; Huang, Chao Hui ; Lloyd, Ken ; Jiang, Da ; Ruiz, Jimmy ; Shi, Yuankai ; Zhang, Liangming ; Liu, Bin ; Cao, Lejie ; Sun, Yan ; Sujith, Kalmadi R ; Chen, Gongyan ; Mao, Weidong ; Kalmadi, R Sujith ; Zhou, Jian-ying ; Wong, Matthew ; Feinstein, Trevor ; Kloecker, Goetz H ; Li, Xiaoling ; Shunyakov, Leonid V ; Thara, Eddie

BACKGROUNDThere is an unmet need for second-line and third-line treatments that are effective and tolerable for advanced or metastatic non-small-cell lung cancer (NSCLC) with no driver mutations.METHODSIn this phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial, we enrolled patients from 58 medical centres in Australia, China, and the USA. Eligible patients were adults with epidermal growth factor receptor (EGFR) wild-type NSCLC who had progressed after first-line platinum-based therapy. Patients were randomly assigned (1:1) using an independent stratified randomisation schedule with a block size of four to receive intravenous docetaxel 75 mg/m² on day 1 and either plinabulin (30 mg/m²) or placebo on days 1 and 8 in 21-day cycles until progression, unacceptable toxic effects, withdrawal, or death. The primary endpoint was overall survival (OS) in the intention-to-treat (ITT) population. Safety was analysed in all patients who had received at least one dose of study drug or placebo. This trial is registered with ClinicalTrials.gov (NCT02504489) and is now closed.FINDINGSBetween Nov 30, 2015, and Jan 6, 2021, 919 patients were screened for inclusion. 360 patients were excluded, and 559 were enrolled and randomly assigned to receive either docetaxel and plinabulin (n=278) or docetaxel and placebo (n=281). 406 (73%) of 559 patients were male, 153 (27%) were female, and 488 (87%) were Asian. Median OS was 10·5 months (95% CI 9·34-11·87) in the plinabulin group compared with 9·4 months (8·38-10·68) in the control group (stratified HR 0·82, 95% CI 0·68-0·99; p=0·0399). Mean OS was 15·08 months (13·42-16·74) in the plinabulin group compared with 12·77 months (11·45-14·10) in the placebo group using restricted mean survival time analysis (difference 2·31 months, 95% CI 0·18-4·44; p=0·0332). Treatment-emergent adverse events occurred in 273 (>99%) of 274 patients in the plinabulin group and 276 (99%) of 278 patients in the control group. Grade 3 or 4 gastrointestinal disorders occurred more frequently in the plinabulin group than in the placebo group, with the most frequent being diarrhoea (24 [9%] of 274 patients vs three [1%] of 278) and vomiting (six [2%] vs one [<1%]), as did transient grade 3 hypertension (50 [18%] vs eight [3%]). Treatment-emergent death was reported in 12 patients (4%) in the plinabulin group and ten patients (4%) in the placebo group.INTERPRETATIONPlinabulin plus docetaxel significantly improved OS as second-line and third-line treatment in patients with advanced or metastatic EGFR wild-type NSCLC and could be considered as a new treatment option in this population.FUNDINGBeyondSpring Pharmaceuticals.

100 Deals associated with Jiangxi Provincial Cancer Hospital

100 Translational Medicine associated with Jiangxi Provincial Cancer Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bifidobacterium/Lactobacillus/Enterococcus(Jiangxi Provincial Cancer Hospital)	Stomatitis More	Clinical
KEX02	Non-Small Cell Lung Cancer More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis